title: I-E+ nonobese diabetic mice develop insulitis and diabetes.
abstract: The development of type I diabetes in the nonobese diabetic (NOD) mouse is under the control of multiple genes, one or more of which is linked to the major histocompatibility complex (MHC). The MHC class II region has been implicated in disease development, with expression of an I-E transgene in NOD mice shown to provide protection from insulitis and diabetes. To examine the effect of expressing an I-E+ or I-E- non-NOD MHC on the NOD background, three I-E+ and three I-E- NOD MHC congenic strains (NOD.H-2i5, NOD.H-2k, and NOD.H-2h2, and NOD.H-2h4, NOD.H-2i7, and NOD.H-2b, respectively) were developed. Of these strains, both I-E+ NOD.H-2h2 and I-E- NOD.H-2h4 mice developed insulitis, but not diabetes. The remaining four congenic strains were free of insulitis and diabetes. These results indicate that in the absence of the NOD MHC, diabetes fails to develop. Each NOD MHC congenic strain was crossed with the NOD strain to produce I-E+ and I-E- F1 mice; these mice thus expressed one dose of the NOD MHC and one dose of a non-NOD MHC on the NOD background. While a single dose of a non-NOD MHC provided a large degree of disease protection to all of the F1 strains, a proportion of I-E+ and I-E- F1 mice aged 5-12 mo developed insulitis and cyclophosphamide-induced diabetes. When I-E+ F1 mice were aged 9-17 mo, spontaneous diabetes developed as well. These data are the first to demonstrate that I-E+ NOD mice develop diabetes, indicating that expression of I-E in NOD mice is not in itself sufficient to prevent insulitis or diabetes. In fact, I-E- F1 strains were no more protected from diabetes than I-E+ F1 strains, suggesting that other non-NOD MHC-linked genes are important in protection from disease. Finally, transfer of NOD bone marrow into irradiated I-E+ F1 recipients resulted in high incidences of diabetes, indicating that expression of non-NOD MHC products in the thymus, in the absence of expression in bone marrow-derived cells, is not sufficient to provide protection from diabetes.
authors.affiliation: Department of Autoimmune Diseases Research, Mercke Research Laboratories, Rahway, New Jersey 07065.
authors.forename: P L
authors.initials: PL
authors.lastname: Podolin
authors.forename: A
authors.initials: A
authors.lastname: Pressey
authors.forename: N H
authors.initials: NH
authors.lastname: DeLarato
authors.forename: P A
authors.initials: PA
authors.lastname: Fischer
authors.forename: L B
authors.initials: LB
authors.lastname: Peterson
authors.forename: L S
authors.initials: LS
authors.lastname: Wicker
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007515:Islets of Langerhans / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD / Q000502:physiology*; D008822:Mice, Transgenic
chemical_list: D000949:Histocompatibility Antigens Class II; C024138:I-E-antigen; D003520:Cyclophosphamide